ITEOS THERAPEUTICS INC (ITOS) Stock Fundamental Analysis

NASDAQ:ITOS • US46565G1040

10.15 USD
+0.02 (+0.2%)
At close: Aug 28, 2025
10.17 USD
+0.02 (+0.2%)
After Hours: 8/28/2025, 8:19:13 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Taking everything into account, ITOS scores 3 out of 10 in our fundamental rating. ITOS was compared to 521 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ITOS as it has an excellent financial health rating, but there are worries on the profitability. ITOS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year ITOS has reported negative net income.
  • ITOS had a negative operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: ITOS reported negative net income in multiple years.
  • In the past 5 years ITOS reported 4 times negative operating cash flow.
ITOS Yearly Net Income VS EBIT VS OCF VS FCFITOS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

1.2 Ratios

  • ITOS has a Return On Assets of -21.57%. This is in the better half of the industry: ITOS outperforms 75.83% of its industry peers.
  • The Return On Equity of ITOS (-27.22%) is better than 79.52% of its industry peers.
Industry RankSector Rank
ROA -21.57%
ROE -27.22%
ROIC N/A
ROA(3y)-7.87%
ROA(5y)-2.39%
ROE(3y)-9.26%
ROE(5y)-0.48%
ROIC(3y)N/A
ROIC(5y)N/A
ITOS Yearly ROA, ROE, ROICITOS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ITOS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ITOS Yearly Profit, Operating, Gross MarginsITOS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • ITOS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, ITOS has more shares outstanding
  • ITOS has more shares outstanding than it did 5 years ago.
  • ITOS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ITOS Yearly Shares OutstandingITOS Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
ITOS Yearly Total Debt VS Total AssetsITOS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • ITOS has an Altman-Z score of 1.90. This is not the best score and indicates that ITOS is in the grey zone with still only limited risk for bankruptcy at the moment.
  • ITOS has a better Altman-Z score (1.90) than 66.79% of its industry peers.
  • ITOS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.9
ROIC/WACCN/A
WACC9.73%
ITOS Yearly LT Debt VS Equity VS FCFITOS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

  • ITOS has a Current Ratio of 7.53. This indicates that ITOS is financially healthy and has no problem in meeting its short term obligations.
  • ITOS's Current ratio of 7.53 is fine compared to the rest of the industry. ITOS outperforms 71.40% of its industry peers.
  • A Quick Ratio of 7.53 indicates that ITOS has no problem at all paying its short term obligations.
  • ITOS has a Quick ratio of 7.53. This is in the better half of the industry: ITOS outperforms 71.96% of its industry peers.
Industry RankSector Rank
Current Ratio 7.53
Quick Ratio 7.53
ITOS Yearly Current Assets VS Current LiabilitesITOS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. Growth

3.1 Past

  • The earnings per share for ITOS have decreased strongly by -43.67% in the last year.
  • Looking at the last year, ITOS shows a very strong growth in Revenue. The Revenue has grown by 177.89%.
  • The Revenue for ITOS have been decreasing by -53.35% on average. This is quite bad
EPS 1Y (TTM)-43.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-694.44%
Revenue 1Y (TTM)177.89%
Revenue growth 3Y-53.35%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

  • The Earnings Per Share is expected to grow by 3.35% on average over the next years.
  • Based on estimates for the next years, ITOS will show a very negative growth in Revenue. The Revenue will decrease by -14.87% on average per year.
EPS Next Y-7.51%
EPS Next 2Y17.23%
EPS Next 3Y13.13%
EPS Next 5Y3.35%
Revenue Next Year-100%
Revenue Next 2Y-61.63%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ITOS Yearly Revenue VS EstimatesITOS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2026 2030 2031 2032 100M 200M 300M
ITOS Yearly EPS VS EstimatesITOS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • ITOS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ITOS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ITOS Price Earnings VS Forward Price EarningsITOS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ITOS Per share dataITOS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • ITOS's earnings are expected to grow with 13.13% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.23%
EPS Next 3Y13.13%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ITOS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

ITEOS THERAPEUTICS INC

NASDAQ:ITOS (8/28/2025, 8:19:13 PM)

After market: 10.17 +0.02 (+0.2%)

10.15

+0.02 (+0.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06
Earnings (Next)11-10
Inst Owners104.81%
Inst Owner Change-53.93%
Ins Owners1.18%
Ins Owner Change-16.79%
Market Cap448.73M
Revenue(TTM)35.00M
Net Income(TTM)-134.41M
Analysts50
Price Target10.56 (4.04%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-10.81%
Min EPS beat(2)-39.15%
Max EPS beat(2)17.53%
EPS beat(4)2
Avg EPS beat(4)-8.08%
Min EPS beat(4)-39.15%
Max EPS beat(4)17.53%
EPS beat(8)6
Avg EPS beat(8)14.15%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-11.92%
PT rev (3m)-11.92%
EPS NQ rev (1m)-6.61%
EPS NQ rev (3m)-10.11%
EPS NY rev (1m)-10.29%
EPS NY rev (3m)-1.39%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.82
P/FCF N/A
P/OCF N/A
P/B 0.91
P/tB 0.91
EV/EBITDA N/A
EPS(TTM)-4.31
EYN/A
EPS(NY)-2.08
Fwd EYN/A
FCF(TTM)-2.46
FCFYN/A
OCF(TTM)-2.44
OCFYN/A
SpS0.79
BVpS11.17
TBVpS11.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -21.57%
ROE -27.22%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-7.87%
ROA(5y)-2.39%
ROE(3y)-9.26%
ROE(5y)-0.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 52.87%
Cap/Sales 1.95%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.53
Quick Ratio 7.53
Altman-Z 1.9
F-Score3
WACC9.73%
ROIC/WACCN/A
Cap/Depr(3y)204.25%
Cap/Depr(5y)178.55%
Cap/Sales(3y)9.83%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-43.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-694.44%
EPS Next Y-7.51%
EPS Next 2Y17.23%
EPS Next 3Y13.13%
EPS Next 5Y3.35%
Revenue 1Y (TTM)177.89%
Revenue growth 3Y-53.35%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-61.63%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y-5.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.22%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y4.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.37%
OCF growth 3YN/A
OCF growth 5YN/A

ITEOS THERAPEUTICS INC / ITOS FAQ

What is the fundamental rating for ITOS stock?

ChartMill assigns a fundamental rating of 3 / 10 to ITOS.


What is the valuation status for ITOS stock?

ChartMill assigns a valuation rating of 0 / 10 to ITEOS THERAPEUTICS INC (ITOS). This can be considered as Overvalued.


Can you provide the profitability details for ITEOS THERAPEUTICS INC?

ITEOS THERAPEUTICS INC (ITOS) has a profitability rating of 1 / 10.


What is the financial health of ITEOS THERAPEUTICS INC (ITOS) stock?

The financial health rating of ITEOS THERAPEUTICS INC (ITOS) is 7 / 10.